Search results
RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035
NBC 17 Raleigh· 4 days agoA host-directed and potentially broad acting twice-daily oral, small molecule, opaganib is in development for multiple indications, including COVID-19, acute respiratory distress syndrome, oncology ...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 2 days agoAlterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 2 days agoCompany to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated
Sentynl Therapeutics Announces Global Acquisition of Zokinvy® (Lonafarnib) for Treatment of...
CBS 47 Fresno· 7 days agoSentynl, a Zydus Group company, receives worldwide proprietary rights to Zokinvy, adding to portfolio of biopharmaceuticals for rare and ultra-rare diseases Zokinvy is approved in the U.S. ( ...
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 4 days agoWebinar, moderated by Cantor Fitzgerald, will be held on Monday, May 13, 2024, at 2:00 p.m. ET Discussion will feature Dr. Michel Michaelides, leading expert in the field of inherited eye disease in adults and children SAN DIEGO, May 06
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 2 days agoTokyo, Japan and Cambridge, UK, 9 May 2024 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the first quarter ended 31 March 2024. The full report
Small Business - Austin Daily Herald | Austin Daily Herald
Austin Daily Herald· 3 days agoRESEARCH TRIANGLE PARK, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2024 financial
Mirum Pharmaceuticals Inc (MIRM) Q1 2024 Earnings Call Transcrip
Guru Focus· 2 days agoFor the complete transcript of the earnings call, please refer to the full earnings call transcript. Mirum Pharmaceuticals Inc (MIRM, Financial) reported a significant increase in total net ...
